首发中东，目的沙特！中美欧获批生物类似药汉曲优®实现中东商业化
内容来源：复宏汉霖
汉曲优®有望成为首个登陆中东行业的国产单抗生物药，再拓海外销售版图
汉曲优®已成功于全球40多个国家和地区获批上市
复宏汉霖首次发货中东地区，实现中国、欧洲、东南亚、拉美、中东商业化供货
2024年6月6日，复宏汉霖自主攻关和生产的汉曲优®（美国商品名：HERCESSI?，欧洲商品名：Zercepac®）正式从公司徐汇基地发出，前往沙特阿拉伯，有望成为首个登陆中东行业的国产单抗生物药。这标志着公司首次商业化发货至中东北非区域，这一里程碑的达成得益于公司与国际团结伙伴Intas及其子公司Accord达成的独家商业化团结，广泛覆盖欧洲、北美、部分中东及北非地区、部分独联体国家行业。
汉曲优®（美国商品名：HERCESSI?，欧洲商品名：Zercepac®）是在中国、欧盟、美国获批的“中国籍”单抗生物类似药，现已成功于美国、英国、法国、德国、瑞士、澳大利亚、芬兰、西班牙、阿根廷、沙特阿拉伯、泰国等超过40个国家和地区获批上市，覆盖亚洲、欧洲、拉丁美洲、北美洲和大洋洲，并进入中国、英国、法国和德国等多个国家的医保目录。截至目前，汉曲优®已惠及逾19万名患者。
复宏汉霖执行董事、首席执行官兼首席财务官
朱俊先生
此次汉曲优®启碇前往沙特，加速拓展至中东及北非市�。酥寥蛐幸担唤鼋鍪歉春旰毫毓驶呗缘奶逑�，也是银河首页官网践行向全球患者提供可负担的高品质生物药的坚定承诺。银河首页官网期待与国际团结伙伴共同奋力，让生命的希望之光传递到每一个需要的角落。
汉曲优®（美国商品名：HERCESSI?, 欧洲商品名：Zercepac®）的攻关、生产和质量控制环节遵循国际最高标准。此次汉曲优®的发货基地徐汇基地是国内首个获得中欧双GMP认证用于生产自主攻关抗体生物药的生产基地。该生产基地及配套的质量经营体系已通过近百项由NMPA、欧洲药品经营局（EMA）、PIC/S成员印尼食品药品监督经营局（BPOM）和巴西国家卫生监督经营局（ANVISA）、欧盟质量受权人（QP）及公司国际商业团结伙伴进行的多项实地核查及审计。2023年，汉曲优®（美国商品名：HERCESSI?, 欧洲商品名：Zercepac®）相关生产场地和设施接受并顺利通过美国FDA的准许前检查（Pre-license Inspection, PLI），复宏汉霖成为通过中国、欧盟、美国GMP认证的自主攻关和生产抗体药物的生物制药银河集团galaxy官网。
围绕汉曲优®，复宏汉霖前瞻性地展开了国际商业化布局，积极开拓海外市�。秩蛏桃低沤峄锇锳ccord、Abbott、Eurofarma、Elea和KGbio等国际一流的生物制药银河集团galaxy官网，全面布局美国、加拿大、欧洲以及众多新兴国家市�。哺侨蛟�100个国家和地区。公司将继续与国际团结伙伴共同推进汉曲优®以及其他产品在国际行业的全球上市进程，惠及更广泛的患者群体。
关于复宏汉霖
Henlius Trastuzumab Begins its Journey to Saudi Arabia
-
HANQUYOU is poised to be the first Chinese monoclonal antibody to enter the? Middle Eastern market, further expanding its global presence -
-
HANQUYOU was approved in more than 40 countries and regions around the world -
-
With the first shipment to the Middle East, Henlius has realized commercialized supply across China, Europe, Southeast Asia, Latin America, and now the Middle East -?
On June 6, 2024, Henlius' independently developed and produced product, HANQUYOU (trade name: HERCESSI? in the U.S. and Zercepac® in Europe), left Henlius’ Xuhui Facility, heading to Saudi Arabia, with the expectation of being the first Chinese monoclonal antibody (mAb) biosimilar to hit the market in the Middle East. This milestone signifies the company’s first commercialized delivery to the Middle East and North African (MENA) countries and is a testament to the exclusive commercial partnership formed with the international partner Intas and its subsidiary Accord, covering parts of Europe, North America, certain areas of MENA, and CIS countries.
Mr. Jason Zhu, Executive Director, Chief Executive Officer and Chief Financial Officer of Henlius stated, “The launch of HANQUYOU to Saudi Arabia, accelerating its expansion to the markets of the MENA, and beyond to the global market, is not only a reflection of Henlius’ globalization strategy but also a solid demonstration of our commitment to providing patients worldwide with quality and affordable biologics. We look forward to working with our global business partners to bring the beacon of hope to every corner of the world that needs it.”
HANQUYOU (trade name: HERCESSI? in the U.S. and Zercepac® in Europe) is a China-developed mAb biosimilar approved in China, the European Union (EU) and U.S. It is now approved in more than 40 countries and regions including the U.S., United Kingdom (UK), France, Germany, Switzerland, Australia, Finland, Spain, Argentina, Saudi Arabia, and Thailand, covering Asia, Europe, Latin America, North America, and Oceania, and it is reimbursed nationally in countries and regions including China, the UK, France and Germany. To date, HANQUYOU has benefited over 190,000 patients.
The development, manufacturing and the quality management system of HANQUYOU (trade name: HERCESSI? in the U.S. and Zercepac® in Europe) are in line with global standards. The Xuhui Facility, from which HANQUYOU has been shipped, is the first plant in China that has obtained dual GMP certifications from China and Europe to manufacture self-developed antibodies. Also, the facility has successfully passed the on-site inspection conducted by NMPA, the European Medicines Agency (EMA), the EU qualified person, and PIC/S members Indonesia Food and Drug Administration (BPOM) and Brazilian National Health Surveillance Agency (ANVISA), as well as multiple international business partners. In 2023, the manufacturing site and facility where HANQUYOU is manufactured underwent and successfully passed the Pre-License Inspection (PLI) by the FDA. The success of the FDA PLI, as well as the previous GMP certifications from China and EU regulatory agencies, makes Henlius a biopharmaceutical company GMP-certificated by China, the EU and U.S. for the manufacturing of self-developed antibody drugs.
About Henlius
